Share
   
Title
Code
Session Type
Venue
Date Time
Chair:
Organizer:

HIV/AIDS remains a major global health challenge with 37 million people living with HIV, and over 2 million new infections every year. New biomedical prevention strategies (such as PrEP and PEP), can make a substantial contributions to halting HIV, but may be difficult to sustain in the long-term. Research is ongoing into non-ARV based interventions, and a vaccine could still present the most effective public health tool in combating HIV/AIDS. As one of the new initiatives launched by the European Commission, the European HIV Vaccine Alliance (EHVA) aims to develop improved vaccine candidates and tools predictive of immunogenicity and of correlates of protection. This EHVA-hosted satellite symposium will provide an overview of the latest developments in HIV prevention broadly, and prophylactic and therapeutic HIV vaccines in particular, as well as introduce key areas of work for EHVA.

12:30
SUSA1101
Welcome and introduction
Yves Lévy, Institut national de la santé et de la recherche médicale (Inserm), France
Slides
12:45
SUSA1102
The EU’s research strategy and its impact on the HIV vaccine landscape
Alessandra Martini, European Commission DG Research and Innovation, Belgium
12:55
SUSA1103
A review of HIV prevention: advances, challenges and new approaches
Glenda Gray, South African Medical Research Council, South Africa
13:15
SUSA1104
HIV envelope proteins: where we are and where we are going
Winfried Weissenhorn, Institute for Structural Biology (IBS), France
13:25
SUSA1105
The role of non-neutralising antibodies in preventing HIV infection
Susan Barnett, Bill and Melinda Gates Foundation, United States
13:35
SUSA1106
Progress in achieving a functional cure and identifying virological and immunological markers
Giuseppe Pantaleo, Swiss Vaccine Research Institute, Switzerland
13:45
SUSA1107
PANEL DISCUSSION
Glenda Gray, South African Medical Research Council, South Africa
Alessandra Martini, European Commission DG Research and Innovation, Belgium
Winfried Weissenhorn, Institute for Structural Biology (IBS), France
Susan Barnett, Bill and Melinda Gates Foundation, United States
Giuseppe Pantaleo, Swiss Vaccine Research Institute, Switzerland
Stefano Vella, Istituto Superiore di Sanità (Italian National Institute of Health), Italy
Ralf Wagner, Institute of Medical Microbiology and Hygiene, Regensburg University, Germany
Jean-Daniel Lelièvre, Vaccine Research Institute (VRI), France
Giulio Maria Corbelli, European AIDS Treatment Group, Italy